<DOC>
	<DOCNO>NCT00465426</DOCNO>
	<brief_summary>HIV-infected patient treat combination antiretroviral therapy demonstrate metabolic abnormality may predispose cardiovascular disease . In HIV-infected patient investigate progression rate cardiovascular disease ass whether progression rate predict increased inflammatory index .</brief_summary>
	<brief_title>HIV Cardiovascular Risk</brief_title>
	<detailed_description>HIV-infected patient treat combination antiretroviral ( ARV ) therapy increasingly demonstrate metabolic abnormality , include dyslipidemia , insulin resistance body composition abnormality may predispose cardiovascular disease ( CVD ) . Initial study suggest increase carotid intima-media thickness ( IMT ) endothelial dysfunction population . Increased carotid IMT time demonstrate HIV-infected patient compare control subject . However , traditional risk factor , dyslipidemia , diabetes mellitus body composition change alone fully predict increase cardiovascular disease HIV-infected patient . One possible explanation increase inflammation , relate directly effect ARV therapy indirectly change fat distribution . In preliminary study , group show change fat distribution highly predictive TNF IL-6 , well adiponectin , specific inflammatory cytokine relate cross-sectional study increase IMT . In propose study investigate use detailed methodology relationship adipocytokine concentration subclinical atherosclerosis cross-sectional longitudinal study . We determine HIV-infected patient ARVs great 6 month , progression rate IMT whether progression rate predict increased inflammatory index , control traditional risk factor , body composition change . We test hypothesis inflammation , traditional risk factor ARV use , mediate subclinical atherosclerotic disease HIV-infected patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Inclusion Criteria Group 1 ( HIVinfected group ) 1 . Age great equal 18 less equal 65 year age 2 . HIV positive , combination ARV regimen &gt; 6 month , include limit either 2 NRTIs NNRTI PI , triple NRTI regimen 3 . CD4 &gt; 350 cells/mm3 Inclusion Criteria Group 2 ( HIV Negative , Healthy Control , age BMI match HIV subject ) 1 . No history HIV infection ( negative HIV test ) 2 . Age great equal 18 less equal 65 year age Exclusion Criteria Group 1 ( HIVinfected group ) 1 . Hgb &lt; 10.0 g/dL , creatinine &gt; 1.5 mg/dL , SGPT &gt; 2.5x ULN 2 . Use glucocorticoid , testosterone , growth hormone anabolic agent within past 6 month 3 . New antiretroviral regimen within 6 month study initiation 4 . Active substance abuse 5 . Medications know affect glucose body composition 6 . Positive pregnancy test recently pregnant within past year lactate 7 . Presence active cancer 8 . Acute viral , bacterial infection ( exclude HIV ) 9 . Weight loss past 3 month great 10 pound Criteria Group 2 ( HIV Negative , Healthy Control , age BMI match HIV subject ) 1 . Hgb &lt; 10.0 g/dL , creatinine &gt; 1.5 mg/dL , SGPT &gt; 2.5x ULN 2 . Use glucocorticoid , testosterone , growth hormone anabolic agent within past 6 month . 3 . Active substance abuse 4 . Medications know affect glucose body composition 5 . Positive pregnancy test recently pregnant within past year lactate 6 . Acute viral , bacterial infection 7 . Weight loss past 3 month great 10 pound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>Inflammatory Markers</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>